



US 20120252834A1

(19) **United States**(12) **Patent Application Publication**
Krakauer et al.(10) **Pub. No.: US 2012/0252834 A1**(43) **Pub. Date: Oct. 4, 2012**(54) **NOVEL USE AND METHOD OF RAPAMYCIN
TO TREAT TOXIC SHOCK****Related U.S. Application Data**(60) Provisional application No. 61/231,348, filed on Aug.
5, 2009.(75) Inventors: **Teresa Krakauer**, Fort Detrick,
MD (US); **Marilyn Buckley**, Fort
Detrick, MD (US)**Publication Classification**(73) Assignee: **The Government Of United
States, As Represented By The
Secretary Of The Army**(51) **Int. Cl.**
A61K 31/436 (2006.01)
C07D 491/16 (2006.01)
A61P 31/00 (2006.01)(21) Appl. No.: **13/387,299**(52) **U.S. Cl.** **514/291; 546/90**(22) PCT Filed: **Aug. 4, 2010**(86) PCT No.: **PCT/US2010/044342**(57) **ABSTRACT**§ 371 (c)(1),
(2), (4) Date: **Jun. 11, 2012**

Rapamycin is used for prevention and treatment of toxic shock. The toxic shock is induced, for example, by a toxin, such as *Staphylococcal* enterotoxin A (SEA), *Staphylococcal* enterotoxin B (SEB), toxic shock syndrome toxin 1 (TSST-I), *streptococcal* pyrogenic exotoxin A (SPEA), and *streptococcal* pyrogenic exotoxin C (SPEC).